Rizwana Sproule - Kite Pharma Vice President - Regulatory Affairs
President
Dr. Rizwana F. Sproule Ph.D. is the Vice President Regulatory Affairs of the Company since January 2014. Prior to joining us Dr. Sproule held senior positions at Amgen Inc. a biopharmaceutical company including Executive Director Therapeutic Area Head for Oncology Global Regulatory Affairs from September 2011 to January 2014 and Director Global Regulatory Leader Global Regulatory Affairs from August 2008 to September 2011 since 2014.
Age | 52 |
Tenure | 10 years |
Professional Marks | Ph.D |
Phone | 310 824-9999 |
Web | www.kitepharma.com |
Kite Pharma Management Efficiency
Kite Pharma's management efficiency ratios could be used to measure how well Kite Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
John Wall | Cadence Design Systems | 53 | |
Andy Larkin | Summit Materials | N/A | |
Deon MacMillan | Summit Materials | 47 | |
Michael Brady | Summit Materials | 51 | |
Thomas Beck | Summit Materials | 67 | |
Mikel Evans | Summit Materials | 47 | |
Noel Ryan | Summit Materials | N/A | |
Douglas Rauh | Summit Materials | 55 | |
CHINCHI TENG | Cadence Design Systems | 58 | |
Neil Zaman | Cadence Design Systems | 49 | |
Anne Benedict | Summit Materials | 46 | |
Damian Murphy | Summit Materials | 46 | |
Surendra Mandava | Cadence Design Systems | 59 | |
Kevin Gill | Summit Materials | 55 | |
Brian Harris | Summit Materials | 68 | |
Martin Lund | Cadence Design Systems | 46 | |
Charlie Huang | Cadence Design Systems | 49 | |
James Cowie | Cadence Design Systems | 53 | |
Karli Anderson | Summit Materials | 51 | |
Karl Watson | Summit Materials | 53 |
Management Performance
Return On Equity | -0.0063 | |||
Return On Asset | -1.0E-4 |
Kite Pharma Leadership Team
Elected by the shareholders, the Kite Pharma's board of directors comprises two types of representatives: Kite Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kite. The board's role is to monitor Kite Pharma's management team and ensure that shareholders' interests are well served. Kite Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kite Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ran Nussbaum, Independent Director | ||
Jonathan Peacock, Independent Director | ||
Shawn Tomasello, Chief Commercial Officer | ||
Jian Irish, Senior Vice President - Supply Chain | ||
Cynthia Butitta, CFO and COO | ||
Franz Humer, Director | ||
Timothy Moore, Executive Vice President - Technical Operations | ||
Jeffrey Wiezorek, Vice President - Clinical Development | ||
Ian Clark, Independent Director | ||
Steven Ruchefsky, Independent Director | ||
Joshua Kazam, Director | ||
Helen Kim, Executive Vice President - Business Development | ||
Helen MBA, Executive VP of Bus. Devel. | ||
David Bonderman, Lead Independent Director | ||
David Chang, Executive Vice President - Research and Development, Chief Medical Officer | ||
Arie Belldegrun, Executive Chairman of the Board and Presidentident, CEO, Founder | ||
Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations | ||
Owen Witte, Director | ||
Paul Jenkinson, CFO | ||
Marc Better, VP of Translation Medicine | ||
Farah Champsi, Independent Director | ||
Roy Doumani, Independent Director | ||
Rizwana Sproule, Vice President - Regulatory Affairs | ||
Margo Roberts, Chief Scientific Officer |
Kite Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kite Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0063 | |||
Return On Asset | -1.0E-4 | |||
Current Valuation | 9.5 B | |||
Shares Outstanding | 57.36 M | |||
Shares Owned By Insiders | 6.93 % | |||
Shares Owned By Institutions | 90.47 % | |||
Number Of Shares Shorted | 8.08 M | |||
Price To Earning | (25.85) X | |||
Price To Book | 14.47 X | |||
Price To Sales | 320.94 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Kite Stock
If you are still planning to invest in Kite Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kite Pharma's history and understand the potential risks before investing.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |